Accueil   Diary - News   All news Transgene and BioInvent collaborate to develop multifunctional viruses for the treatment of solid tumors

Transgene and BioInvent collaborate to develop multifunctional viruses for the treatment of solid tumors

 

 

Strasbourg (France) and Lund (Sweden), March 26, 2019, 8:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors and BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immunoregulatory antibodies to treat cancer, announce the extension of their collaboration to co-develop multi-functional oncolytic viruses (OV) encoding for undisclosed antibodies sequences capable of treating a broad range of solid tumors.

 

Read the press release